Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10863254 | 0.84 | CYP3A4 (0.59) | CYP3A4MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25281976 | 0.81 | CYP3A4 (0.76) | CYP3A4MAPTSMN1; SMN2TAAR1 | |
| SCHEMBL16870383 | 0.81 | CYP3A4 (0.65) | CYP3A4MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4056768 | 0.81 | ALDH1A1 (0.40) | CYP3A4MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL12551767 | 0.80 | TAAR1 (0.43) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10862987 | 0.80 | CYP3A4 (0.64) | CYP3A4MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4061805 | 0.79 | PDE4A (0.47) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4056315 | 0.77 | TAAR1 (0.43) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1753946 | 0.75 | TAAR1 (0.50) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3323483 | 0.74 | HSD17B10 (0.53) | CYP3A4MAPTMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-12-24 | — | — | US | disclosed |
| EP-2079744-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| EP-1972631-A1 | Imidazopyridazines as PI3K lipid kinase inhibitors | Novartis AG (CH) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008052733-A1 | IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318410-A1 | IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS | PI4KA, PIK3CA, PIK3CB | CYP3A4 965/4885MAPT 4252/4885MEN1 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.